EyeGate Pharmaceuticals Inc reports results for the quarter ended in June - Earnings Summary

Kiora Pharmaceuticals

13/08/2021 05:45

* EyeGate Pharmaceuticals Inc  EYEG.OQ  reported a quarterly
adjusted loss of 35 cents​​ per share for the quarter ended in
June. The mean expectation of three analysts for the quarter was
for a loss of 42 cents per share.
* Reported revenue was zero​;  analysts expected zero. 
* EyeGate Pharmaceuticals Inc's reported EPS for the quarter was
a loss of 35 cents​.
* The mean earnings estimate of analysts had fallen by
about 2.9% in the last three months.​ 
* In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
* EyeGate Pharmaceuticals Inc shares had fallen by 52.5% this
quarter and lost 64.9% so far this year.
* The company reported a quarterly loss of $2.47 million.
* Wall Street's median 12-month price target for EyeGate
Pharmaceuticals Inc is $14.00 
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
This summary was machine generated August 13 at 04:45 a.m.  ​All
figures in US dollars unless otherwise stated